PMC:7283670 / 73654-73932 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T407","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"T408","span":{"begin":137,"end":145},"obj":"Disease"}],"attributes":[{"id":"A407","pred":"mondo_id","subj":"T407","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A408","pred":"mondo_id","subj":"T408","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names:"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T639","span":{"begin":157,"end":159},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names:"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T292","span":{"begin":108,"end":112},"obj":"Chemical"},{"id":"T293","span":{"begin":243,"end":245},"obj":"Chemical"}],"attributes":[{"id":"A292","pred":"chebi_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A293","pred":"chebi_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"}],"text":"Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names:"}

{"project":"LitCovid-sentences","denotations":[{"id":"T684","span":{"begin":0,"end":278},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names:"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1921","span":{"begin":67,"end":75},"obj":"Species"}],"attributes":[{"id":"A1921","pred":"tao:has_database_id","subj":"1921","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names:"}